Purus Wealth Management’s Regeneron Pharmaceuticals REGN Stock Holding History

Purus Wealth Management’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-310	Closed	-$240K	–	174
2026 Q1	$240K	Hold	310	–	–	0.08%	138
2025 Q4	$239K	Buy	+310	New	+$211K	0.07%	128
2025 Q1	–	Sell	-300	Closed	-$214K	–	123
2024 Q4	$214K	Hold	300	–	–	0.08%	114
2024 Q3	$315K	Hold	300	–	–	0.13%	89
2024 Q2	$315K	Hold	300	–	–	0.14%	87
2024 Q1	$289K	Hold	300	–	–	0.14%	90
2023 Q4	$263K	Hold	300	–	–	0.15%	104
2023 Q3	$247K	Hold	300	–	–	0.17%	100
2023 Q2	$216K	Hold	300	–	–	0.14%	113
2023 Q1	$247K	Hold	300	–	–	0.19%	101
2022 Q4	$216K	Hold	300	–	–	0.2%	102
2022 Q3	$207K	Buy	+300	New	+$189K	0.19%	99
2022 Q2	–	Sell	-300	Closed	-$210K	–	108
2022 Q1	$210K	Buy	+300	New	+$190K	0.15%	108

Other funds holding REGN

Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

MCI

McDonald Capital Investors Orinda, California $1.37B AUM 1.88% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return

Retirement Systems of Alabama Montgomery, Alabama $33.2B AUM 38.15% 1-Year Est. Return

New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return

Parnassus Investments San Francisco, California $37.4B AUM 35.42% 1-Year Est. Return

Purus Wealth Management's REGN Position: Q2 2026 in Review

Purus Wealth Management sold out of Regeneron Pharmaceuticals (REGN) in Q2 2026, closing a stake of 310 shares — an estimated $240K sold.

Purus Wealth Management first reported a position in REGN in Q1 2022 and held it in 13 quarters. The position peaked at $315K in Q3 2024. 518 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

Purus Wealth Management reported no remaining Regeneron Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
Purus Wealth Management sold 310 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $240K.
Purus Wealth Management first reported a position in Regeneron Pharmaceuticals in Q1 2022 and held it in 13 quarters.
Purus Wealth Management's Regeneron Pharmaceuticals position peaked at $315K in Q3 2024.
518 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on Purus Wealth Management's 13F filing for Q2 2026, filed 13 Jul 2026.